Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab

被引：95

作者：

Sera, Toshiki ^{[1
]}

Hiasa, Yoichi ^{[1
]}

Michitaka, Kojiro ^{[2
]}

Konishi, Ichiro ^{[1
]}

Matsuura, Kana ^{[1
]}

Tokumoto, Yoshio ^{[1
]}

Matsuura, Bunzo ^{[1
]}

Kajiwara, Takeshi ^{[3
]}

Masumoto, Toshikazu ^{[3
]}

Horiike, Norio ^{[1
]}

Onji, Morikazu ^{[1
]}

机构：

[1] Ehime Univ, Grad Sch Med, Dept Gastroenterol & Metabol, Toon, Japan

[2] Ehime Univ, Grad Sch Med, Dept Endoscop Med, Toon, Japan

[3] Shikoku Canc Ctr, Natl Hosp Org, Toom, Japan

来源：

INTERNAL MEDICINE | 2006年 / 45卷 / 11期

关键词：

hepatitis B virus; reactivation; rituximab;

D O I：

10.2169/internalmedicine.45.1590

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A 59-year-old man developed acute hepatitis with reactivated hepatitis B virus (HBV) following administration of rituximab (anti-CD20 monoclonal antibody). The patient was diagnosed with malignant lymphoma in 1998, and virus marker testing indicated HBV surface antigen (HBsAg)-negative and anti-HBs antibody (anti-HBs)-positive results when chemotherapy including rituximab was started. Levels of aminotransferases were elevated, and HBsAg results turned positive. Despite therapy for late-onset hepatic failure, the patient died. Rituximab appears likely to have induced HBV reactivation in this case. Anti-viral agents should be administered for both HBsAg-positive and anti-HBs-positive patients who are scheduled to receive rituximab.

引用

页码：721 / 724

页数：4